Literature DB >> 17230439

A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gammadelta and alphabeta T cell responses in primates.

Delphine Cendron1, Sophie Ingoure, Angelo Martino, Rita Casetti, Françoise Horand, François Romagné, Hélène Sicard, Jean-Jacques Fournié, Fabrizio Poccia.   

Abstract

Phosphoantigens are mycobacterial non-peptide antigens that might enhance the immunogenicity of current subunit candidate vaccines for tuberculosis. However, their testing requires monkeys, the only animal models suitable for gammadelta T cell responses to mycobacteria. Thus here, the immunogenicity of 6-kDa early secretory antigenic target-mycolyl transferase complex antigen 85B (ESAT-6-Ag85B) (H-1 hybrid) fusion protein associated or not to a synthetic phosphoantigen was compared by a prime-boost regimen of two groups of eight cynomolgus. Although phosphoantigen activated immediately a strong release of systemic Th1 cytokines (IL-2, IL-6, IFN-gamma, TNF-alpha), it further anergized blood gammadelta T lymphocytes selectively. By contrast, the hybrid H-1 induced only memory alphabeta T cell responses, regardless of phosphoantigen. These latter essentially comprised cytotoxic T lymphocytes specific for Ag85B (on average + 430 cells/million PBMC) and few IFN-gamma-secreting cells (+ 40 cells/million PBMC, equally specific for ESAT-6 and for Ag85B). Hence, in macaques, a prime-boost with the H-1/phosphoantigen subunit combination induces two waves of immune responses, successively by gammadelta T and alphabeta T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230439     DOI: 10.1002/eji.200636343

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques.

Authors:  Zahida Ali; Lingyun Shao; Lisa Halliday; Armin Reichenberg; Martin Hintz; Hassan Jomaa; Zheng W Chen
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

2.  Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity.

Authors:  Charles T Spencer; Getahun Abate; Azra Blazevic; Daniel F Hoft
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 3.  γδ T-APCs: a novel tool for immunotherapy?

Authors:  Bernhard Moser; Matthias Eberl
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

4.  Distinctive Leukocyte Subpopulations According to Organ Type in Cynomolgus Macaques.

Authors:  Jonah S Zitsman; Paula Alonso-Guallart; Christopher Ovanez; Yojiro Kato; Joanna F Rosen; Joshua I Weiner; Raimon Duran-Struuck
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

Review 5.  γδ T cell receptor ligands and modes of antigen recognition.

Authors:  Eric Champagne
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-02-06       Impact factor: 4.291

Review 6.  How tumors might withstand γδ T-cell attack.

Authors:  Aude-Hélène Capietto; Ludovic Martinet; Jean-Jacques Fournié
Journal:  Cell Mol Life Sci       Date:  2011-05-06       Impact factor: 9.261

Review 7.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 8.  Diversity of γδ T-cell antigens.

Authors:  Willi K Born; M Kemal Aydintug; Rebecca L O'Brien
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

Review 9.  γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.

Authors:  Serena Meraviglia; Sary El Daker; Francesco Dieli; Federico Martini; Angelo Martino
Journal:  Clin Dev Immunol       Date:  2011-01-05

10.  Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

Authors:  A J Nicol; H Tokuyama; S R Mattarollo; T Hagi; K Suzuki; K Yokokawa; M Nieda
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.